Actively Recruiting
Phase I First-in-Human Dose Escalation Study of 225Ac-AZD2284 with AZD2287 and AZD2275 in Men with Metastatic Castration-Resistant Prostate Cancer
Led by AstraZeneca · Updated on 2026-10-16
136
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of three investigational drugs AZD2284, AZD2287, and AZD2275, in men with metastatic castration-resistant prostate cancer. This first-in-human, open-label Phase I trial includes two parts Part A focuses on imaging to find the best dosing strategy for AZD2287 with or without AZD2275 pre-administration. Part B involves dose escalation of AZD2284 to assess safety, tolerability, and efficacy, including expansion cohorts to explore treatment effects further. Participants receive AZD2287 and may receive AZD2275 depending on the dosing strategy determined in Part A. Eligible participants then receive escalating doses of AZD2284 in Part B. The trial includes several dosing levels and expansion cohorts to characterize safety and efficacy. The study is designed sequentially, with imaging and dosing phases informing each other to optimize treatment administration. During the trial, participants undergo imaging scans such as SPECTCT and planar imaging to evaluate drug distribution and tumor uptake. Researchers monitor adverse events and dose-limiting toxicities up to five years, along with various laboratory tests and pharmacokinetic assessments. Outcome measures include overall response rates, prostate-specific antigen PSA changes, progression-free survival, and overall survival. The studys total duration extends up to five years for long-term safety and effectiveness monitoring.
CONDITIONS
Brief Title
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here